

Date _____

PRIOR AUTH QUESTIONNAIRE- IRESSA®

M.D. Last Name: _____	M.D. First Name: _____
Physician Phone: _____	Physician Fax: _____
Patient _____	ID# _____ DOB _____

TO ENSURE PROMPT PROCESSING PLEASE COMPLETE ALL OF THE QUESTIONS.

IF THIS IS A RENEWAL, PROCEED TO QUESTION #8.

- | | | |
|---|-----|----|
| 1. Patient has stage III or stage IV non-small cell lung cancer. | Yes | No |
| 2. Patient has failed both a platinum-based regimen and a regimen containing docetaxel. | Yes | No |
| 3. Patient's liver function tests are within normal limits (ALT and AST <35 u/L). | Yes | No |
| 4. Patient is 18 years of age or older. | Yes | No |
| 5. Prescriber understands Iressa® is only to be given as monotherapy. | Yes | No |
| 6. Patient began Iressa® therapy prior to September 15, 2005 and is currently benefiting from Iressa® therapy. | Yes | No |
| 7. Patient and prescriber understand that Iressa® cannot be expected to increase survival in patients with NSCLC who have failed other courses of cancer therapy. | Yes | No |
| 8. If this is a renewal: Has the patient demonstrated symptomatic improvement in health-related quality of life? | Yes | No |
| 9. Patient is currently experiencing interstitial lung disease. | Yes | No |

Physician Signature or name of person providing answers _____

Physician Comments _____

Send or Fax completed form to:
877-329-7279

Restat
11900 W. Lake Park Dr.
Milwaukee, WI 53224

QUESTIONS PLEASE CALL:
877-526-9906

www.restat.com

Quantity Limit: 60 tabs per 30 days.

*****DISCLOSURE STATEMENT*****

This transmission may contain information which is confidential, proprietary and privileged. If you are not the individual or entity to which it is addressed, note that any review, disclosure, copying, retransmission or other use is strictly prohibited. If you received this transmission in error, please notify the sender immediately and delete the material from your system. Date 9/1/2010